Cubist Systematic Strategies, LLC Altimmune, Inc. Transaction History

Cubist Systematic Strategies, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.22 - $13.81 $1 Million - $1.69 Million	-122,155 Reduced 84.25%	22,830 $232,000
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $211,500 - $1.15 Million	98,832 Added 214.14%	144,985 $1.63 Million
Q3 2023 Nov 14, 2023	SELL	$2.4 - $3.45 $245,397 - $352,759	-102,249 Reduced 68.9%	46,153 $119,000
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $168,822 - $292,135	48,934 Added 49.2%	148,402 $523,000
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $416,770 - $1.67 Million	99,468 New	99,468 $419,000
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $763,779 - $1.6 Million	71,582 Added 72.04%	170,947 $2.18 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $763,779 - $1.6 Million	71,582 Added 72.04%	170,947 $2.18 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $38,927 - $116,287	9,880 Added 11.04%	99,365 $1.16 Million
Q1 2022 May 16, 2022	SELL	$5.9 - $9.45 $11,245 - $18,011	-1,906 Reduced 2.09%	89,485 $545,000
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $794,187 - $1.14 Million	91,391 New	91,391 $837,000
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $584,199 - $1.16 Million	-69,300 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $600,032 - $1 Million	-60,917 Reduced 46.78%	69,300 $683,000
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $713,247 - $1.36 Million	56,117 Added 75.73%	130,217 $1.84 Million
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $4,845 - $8,787	618 Added 0.84%	74,100 $836,000
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $729,676 - $2.44 Million	73,482 New	73,482 $970,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.